Evidence map›Paper›PMID 31922900›Full record

ArticleAmerican journal of respiratory cell and molecular biology2020

Subacute TGFβ Exposure Drives Airway Hyperresponsiveness in Cystic Fibrosis Mice through the PI3K Pathway.

Elizabeth L Kramer, Satish K Madala, Kristin M Hudock, Cynthia Davidson, John P Clancy

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. TGF-β induces excessive pulmonary IL-6 secretion in cystic fibrosis via PI3K.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Update in Pediatrics 2020.American journal of respiratory and critical care medicine · 2021
    Article
  6. Is PI3K a Villain in Cystic Fibrosis?American journal of respiratory cell and molecular biology · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Elizabeth L KramerDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.ORCID 0000-0002-3278-2161
Satish K MadalaDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Kristin M HudockDivision of Pulmonary Biology, Cincinnati Children's Hospital, Cincinnati, Ohio; and.
Cynthia DavidsonDivision of Pulmonary Medicine and.
John P ClancyDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Pulmonary Associates · USCincinnati Children's Hospital Medical Center · US

Funding

Together: Transforming and Translating Discovery to Improve HealthKL2TR001429 · NCATS · UNIVERSITY OF FLORIDA · PI GUIRGIS, FAHEEM W, LEEUWENBURGH, CHRISTIAAN · 2015 to 2023
$5.5M
WT1 REGULATION OF PULMONARY FIBROSISR01HL134801 · NHLBI · UNIVERSITY OF CINCINNATI · PI MADALA, SATISH K · 2017 to 2025
$3.9M
The NET effect: Human CF epithelial responses to NETosisK08HL124191 · NHLBI · UNIVERSITY OF CINCINNATI · PI HUDOCK, KRISTIN MARA · 2017 to 2021
$901k
NCATS NIH HHS KL2 TR001429NHLBI NIH HHS K08 HL124191NHLBI NIH HHS R01 HL134801
6 · The paper itself

Abstract

Cystic fibrosis (CF) is a lethal genetic disease characterized by progressive lung damage and airway obstruction. The majority of patients demonstrate airway hyperresponsiveness (AHR), which is associated with more rapid lung function decline. Recent studies in the neonatal CF pig demonstrated airway smooth muscle (ASM) dysfunction. These findings, combined with observed CF transmembrane conductance regulator (CFTR) expression in ASM, suggest that a fundamental defect in ASM function contributes to lung function decline in CF. One established driver of AHR and ASM dysfunction is transforming growth factor (TGF) β1, a genetic modifier of CF lung disease. Prior studies demonstrated that TGFβ exposure in CF mice drives features of CF lung disease, including goblet cell hyperplasia and abnormal lung mechanics. CF mice displayed aberrant responses to pulmonary TGFβ, with elevated PI3K signaling and greater increases in lung resistance compared with controls. Here, we show that TGFβ drives abnormalities in CF ASM structure and function through PI3K signaling that is enhanced in CFTR-deficient lungs. CF and non-CF mice were exposed intratracheally to an adenoviral vector containing the TGFβ1 cDNA, empty vector, or PBS only. We assessed methacholine-induced AHR, bronchodilator response, and ASM area in control and CF mice. Notably, CF mice demonstrated enhanced AHR and bronchodilator response with greater ASM area increases compared with non-CF mice. Furthermore, therapeutic inhibition of PI3K signaling mitigated the TGFβ-induced AHR and goblet cell hyperplasia in CF mice. These results highlight a latent AHR phenotype in CFTR deficiency that is enhanced through TGFβ-induced PI3K signaling.

Indexed as

Signal TransductionAdrenergic beta-AgonistsAlbuterolAnimalsBronchoconstrictionCystic FibrosisGoblet CellsHyperplasiaLungMice, Inbred C57BLMuscle, SmoothPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsRespiratory HypersensitivityTransforming Growth Factor betaAdrenergic beta-AgonistsAlbuterolPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsTransforming Growth Factor betaairway hyperresponsivenessairway smooth muscleCFTRcystic fibrosistransforming growth factor β

Identifiers

PMID31922900
PMCPMC7193791
OpenAlexW3021199766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.